Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 801–900 of 1,013
QSAR analysis and molecular modeling of ABCG2-specific inhibitors
Nicolle, E., Boumendjel, A., Macalou, S., Genoux, E., Ahmed-Belkacem, A., Carrupt, P.-A., & Di Pietro, A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.10.004 · Cited by 71
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy
Gupta, S. K., Singh, P., Ali, V., & Verma, M. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.448 · Cited by 79
Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response
Nies, A. T., Magdy, T., Schwab, M. G., & Zanger, U. M. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.007 · Cited by 87
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)
Hardwick, L., Velamakanni, S., & van Veen, H. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707218 · Cited by 79
“, 2002), information on the relevance of ABCG2 in clinical MDR is still limited (Leonard et al., 2003; Szakacs et al., 2006).”
BackgroundLiu, C., Zhao, Y., Wang, J., Yang, Y., Zhang, Y., Qu, X., Peng, S., Yao, Z., Zhao, S., He, B., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.042 · Cited by 72
Goebel, J., Chmielewski, J. A., & Hrycyna, C. A. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.19 · Cited by 101
“Unfortunately, many inhibitors of P-gp and ABCG2 that were successful in vitro did not prove to be efficacious in these human trials[3,17,19,27,29,57,58].”
BackgroundResultInfluentialQian, K., Fu, W., Li, T., Zhao, J., Lei, C., & Hu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02492-1 · Cited by 78
“In addition to the induction of EMT, the molecules carried by TDsEVs can activate intracellular anti-apoptotic pathways [33, 34] and induce drug efflux or sequestration [35].”
BackgroundA literature review of the promising future of TROP2: a potential drug therapy target
Wen, Y., Ouyang, D., Zou, Q., Chen, Q., Luo, N., He, H., Anwar, M., & Yi, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5976 · Cited by 85
“Since SN-38 is susceptible to multiple ABC transporters (75), some patients with metastatic triplenegative breast cancer (mTNBC) showed early disease progression, thus failing IMMU-132.”
BackgroundYu, H., Xu, Z., Chen, X., Xu, L., Yin, Q., Zhang, Z., & Li, Y. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201300282 · Cited by 70
Jatrophane diterpenes from Euphorbia spp. as modulators of multidrug resistance in cancer therapy
Corea, G., Pietro, A. D., Dumontet, C., Fattorusso, E., & Lanzotti, V. (2009) · Phytochemistry Reviews · doi:10.1007/s11101-009-9126-8 · Cited by 80
“Indeed, no significant inhibition was observed for any compound up to a 20 lM concentration, whereas the control inhibitor GF120918 gave a submicromolar IC50 value, in agreement with previous observations (AhmedBelkacem et al. 2005; Szakacs et al. 2006).”
BackgroundResultInfluentialBypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies
Jin, Y., Li, Jin, Y., Xie, Yao, Li, & Qiu (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27864 · Cited by 70
“After a long period of chemotherapy, many patients suffer from MDR, which can reduce therapy efficiency and lead to treatment failure.(1) The high level of resistance is usually caused by complex MDR mechanisms.”
Vitamin E reverses multidrug resistance in vitro and in vivo
Tang, J., Fu, Q., Wang, Y., Racette, K., Wang, D., & Liu, F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.020 · Cited by 71
“Many studies with multidrug resistant cells correlated resistance to reduced accumulation of drugs within the cells due to their increased efflux or decreased influx by P-gp [2,39,40].”
BackgroundTeng, Y., Sheu, M., Hsieh, Y., Wang, R., Chiang, Y., & Hung, C. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.01.008 · Cited by 70
Kraege, S., Stefan, K., Juvale, K., Ross, T., Willmes, T., & Wiese, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.067 · Cited by 82
Chan, K., Wong, I. L. K., Kan, J. W. Y., Yan, C. S. W., Chow, L. M. C., & Chan, T. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201121b · Cited by 71
Eldehna, W. M., Al-Wabli, R. I., Almutairi, M. S., Keeton, A. B., Piazza, G. A., Abdel‐Aziz, H. A., & Attia, M. I. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1462802 · Cited by 70
Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption
Ha, J. S., Byun, J., & Ahn, D. (2016) · Scientific Reports · doi:10.1038/srep22847 · Cited by 71
Ghanbarian, M., Afgar, A., Yadegarazari, R., Najafi, R., & Teimoori‐Toolabi, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.112 · Cited by 71
Yu, H., Li, J., Deng, K., Zhou, W., Wang, C., Wang, Q., Li, K., Zhao, H., & Huang, S. (2019) · Theranostics · doi:10.7150/thno.35748 · Cited by 69
“MDR is one of the biggest challenges in cancer chemotherapy and has resulted in more than 90% of clinical chemotherapy failures [3,4].”
BackgroundGoard, C. A., Mather, R. G., Vinepal, B., Clendening, J. W., Martirosyan, A., Boutros, P. C., Sharom, F. J., & Penn, L. Z. (2010) · International Journal of Cancer · doi:10.1002/ijc.25295 · Cited by 71
“Classical MDR occurs when tumor cells develop cross-resistance to drugs of diverse structure and function, and may play a role in the failure of chemotherapy in several malignancies.(13,14) It has been well defined in cell culture systems that, in MDR tumor cells, upregulation of P-gp expression and activity can preve…”
BackgroundRhodamine Inhibitors of P-Glycoprotein: An Amide/Thioamide “Switch” for ATPase Activity
Gannon, M. K., Holt, J. J., Bennett, S. M., Wetzel, B. R., Loo, T. W., Bartlett, M. C., Clarke, D. M., Sawada, G. A., Higgins, J. W., Tombline, G., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900253g · Cited by 74
Maruthanila, V. L., Jayakumar, P., & Mirunalini, S. (2014) · Advances in Pharmacological Sciences · doi:10.1155/2014/832161 · Cited by 69
Frasco, M. F., Almeida, G. M., Santos‐Silva, F., Pereira, M. D. C., & Coelho, M. A. N. (2014) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35286 · Cited by 72
“One of the most characterized drug efflux pumps playing a significant role in drug resistance is Pglycoprotein, a cell-surface glycoprotein member of the ATPbinding cassette (ABC) transporters.(8) Thus, another possibility to overcome MDR includes direct inhibition of P-”
BackgroundCircumvention of multi-drug resistance of cancer cells by Chinese herbal medicines
Chai, S., To, K. K., & Lin, G. (2010) · Chinese Medicine · doi:10.1186/1749-8546-5-26 · Cited by 69
“P-glycoprotein (Pgp), multidrug-resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP/ABCG2) is frequently observed in cancer cell lines selected with chemotherapeutic drugs [6] and critical to clinical drug resistance [7].”
BackgroundChakrabarti, S., & Michor, F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2871 · Cited by 72
Natural products—friends or foes?
Margina, D. M., Ilie, M., Grădinaru, D., Androutsopoulos, V. P., Kouretas, D., & Tsatsakis, A. M. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.05.009 · Cited by 72
“…(or ATP-binding cassette sub-family B member 1- ABCB1), multidrug resistance-associated protein 1 (MDR1, or MRP1), multidrug resistance-associated protein 2 (MDR2, or MRP2), breast cancer resistance protein (BCRP or ABCG2), etc. (Szakacs et al., 2006; Abraham et al., 2012; Estudante et al., 2013).”
BackgroundRecent progress in nitric oxide-generating nanomedicine for cancer therapy
Li, Y., Yoon, B., Dey, A., Nguyen, V. Q., & Park, J. H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.012 · Cited by 70
Xu, M., Gong, A., Yang, H., George, S. K., Jiao, Z., Huang, H., Jiang, X., & Zhang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.005 · Cited by 68
The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms
Isaac, M. B., Siu, A., & Jongstra, J. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.04.002 · Cited by 72
“The MDR1/ABCB1/P-glycoprotein is a member of the superfamily of transmembrane ABC transporter proteins that efflux a large number of structurally diverse, mainly hydrophobic compounds from cells, but each transporter has their own specific substrates (Szakacs et al., 2006).”
Chowdhury, E. H., Li, X., Chu, & Kunnath (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30500 · Cited by 68
“International Journal of Nanomedicine 2012:7 ABCB1 transporter or P-glycoprotein, the first cytotoxic drug efflux pump to be identified,(12) functions by actively extruding drugs including anthracyclines, taxanes, and vinca alkaloids out of cancer cells, thus reducing intracellular drug concentration below the thresho…”
Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance
Abraham, I., Sayed, K. A. E., Chen, Z., & Guo, H. (2012) · Marine Drugs · doi:10.3390/md10102312 · Cited by 72
“These sipholanes had no effect on the response to cytotoxic agents in MRP1-, MRP7- and BCRP-overexpressing cells.”
BackgroundInfluentialZhu, Y., Liu, C., Armstrong, C. M., Lou, W., Sandher, A., & Gao, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0269 · Cited by 74
Redundancy: A Critical Obstacle to Improving Cancer Therapy
Lavi, O. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3256 · Cited by 68
“For instance, the multidrug transporters ABCB1, ABCC1, and ABCG2 share many substrates (32).”
BackgroundSpindler, A., Stefan, K., & Wiese, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00035 · Cited by 68
Yang, R., Mondal, G., Wen, D., & Mahato, R. I. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.07.017 · Cited by 72
Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells
Zheng, A.-W., Chen, Y., Zhao, L., & Feng, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6031 · Cited by 68
“Previous studies have indicated that MDR1/P-glycoprotein has an important role in the exclusion of drugs from tumor cells (24,25).”
Mitochondrial Surface Engineering for Multidrug Resistance Reversal
Chen, W., Shi, K., Chu, B., Wei, X., & Qian, Z. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b05188 · Cited by 68
Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents
Zhao, J., & Feng, S. (2015) · Nanomedicine · doi:10.2217/nnm.15.61 · Cited by 75
Martinez, L., Arnaud, O., Hénin, É., Tao, H., Chaptal, V., Doshi, R., Andrieu, T., Dussurgey, S., Tod, M. M., Pietro, A. D., et al. (2013) · FEBS Journal · doi:10.1111/febs.12613 · Cited by 68
microRNAs, an active and versatile group in cancers
Liu, J., Zheng, M. H., Tang, Y., Liang, X., & Yang, Q. (2011) · International Journal of Oral Science · doi:10.4248/ijos11063 · Cited by 72
Detergents as intrinsic P-glycoprotein substrates and inhibitors
Li‐Blatter, X., Nervi, P., & Seelig, A. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.07.010 · Cited by 68
Biological rationale for the design of polymeric anti-cancer nanomedicines
Zhou, Y., & Kopec̆ek, J. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.723213 · Cited by 72
“…include the overexpression of drug efflux pumps commonly characterized by ATP-binding cassette family such as P-glycoprotein (P-gp), detoxification processes, enhanced DNA repair, or the imbalance of pro- and antiapoptotic pathways (Dean et al., 2005; Szakács et al., 2006; Broxterman et al., 2009).”
BackgroundSonoporation: Applications for Cancer Therapy
Qin, J., Wang, T.-Y., & Willmann, J. K. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22536-4_15 · Cited by 73
“An example is the multidrug resistance associated protein pumps, also known as P-glycoproteins, which are exporters of ATPbinding cassette transporters (Gottesman 2002; Szakacs et al. 2006).”
Yuan, Y., & Liu, B. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am5020925 · Cited by 67
Isgut, M., Mukkavilli, R., Yang, C., Subrahmanyam, V., Rida, P. C. G., & Aneja, R. (2017) · Medicinal Research Reviews · doi:10.1002/med.21444 · Cited by 69
Wang, Q., Zhang, X., Liao, H., Sun, Y., Ding, L., Teng, Y., Zhu, W., Zhang, Z., & Duan, Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201706124 · Cited by 69
Vargas, J. R., Stanzl, E. G., Teng, N. N. H., & Wender, P. A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500161z · Cited by 72
Reversing Multidrug Resistance by Multiplexed Gene Silencing for Enhanced Breast Cancer Chemotherapy
Li, Y., Gao, X., Yu, Z., Liu, B., Pan, W., Li, N., & Tang, B. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b02800 · Cited by 66
ArulJothi, K. N., Kumaran, K., Senthil, S., Nidhu, A. B., Munaff, N., Babu, J. V., Kirubakaran, R., Singh, S. K., Gupt, G., Dua, K., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01900-y · Cited by 72
Chen, F., Kang, R., Liu, J., & Tang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1213995 · Cited by 79
“Drug resistance is a major contributor to treatment failure in cancer patients, resulting from multiple mechanisms (Szakacs et al., 2006).”
BackgroundImportance of ABCC1 for cancer therapy and prognosis
Kunická, T., & Souček, P. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.901348 · Cited by 79
“…genes responsible for encoding these proteins, as well as other genes encoding additional ABC transporters known to be involved in anticancer drug resistance are shown in Table 1, along with examples of the established substrates of each ABC transporter (Moitra et al., 2011; Szakács et al., 2006).”
BackgroundInfluentialTotal Synthesis and Evaluation of a Key Series of C5-Substituted Vinblastine Derivatives
Va, P., Campbell, E., Robertson, W. M., & Boger, D. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1027748 · Cited by 66
Ferreiro, J. F., Rouhi, L., Urbánková, H., van der Krogt, J., Michaux, L., Shetty, S., Krenács, L., Tousseyn, T., Paepe, P. D., Uyttebroeck, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102977 · Cited by 66
“These molecules, which function in normal biology to protect cells from harmful toxins and xenobiotics, contribute to drug resistance of cancers by extruding a variety of chemotherapeutic agents from the tumor cells [46].”
BackgroundMahajan, A., Goh, V., Basu, S. K., Vaish, R., Weeks, A. J., Thakur, M., & Cook, G. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.06.082 · Cited by 71
Quaternized starch-based carrier for siRNA delivery: From cellular uptake to gene silencing
Amar‐Lewis, E., Azagury, A., Chintakunta, R., Goldbart, R., Traitel, T., Prestwood, J., Landesman‐Milo, D., Peer, D., & Kost, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.031 · Cited by 67
“NAR cell line overexpresses the gene ABCB1, which encodes for the expression of P-gp [32].”
Antibody-drug conjugates: Current status and future perspectives
Gébleux, R., & Casi, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.012 · Cited by 74
Colla, R., Izzotti, A., Ciucis, C. D., Fenoglio, D., Ravera, S., Speciale, A., Ricciarelli, R., Furfaro, A. L., Pulliero, A., Passalacqua, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12209 · Cited by 70
“Based on the fact that chemoresistance often transforms into multi-drug resistance (MDR), which characterizes highly malignant neuroblastoma [35, 36], HTLA-Chr and parental cells were exposed to high doses of etoposide or doxorubicin using concentrations equal to, or higher than, those used to treat patients [18, 37].”
Bajerski, L., Michels, L. R., Colomé, L. M., Bender, E. A., Freddo, R. J., Bruxel, F., & Haas, S. E. (2016) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502016000300001 · Cited by 70
“Development of multidrug resistance against a variety of conventional and novel chemotherapeutic agents is a significant challenge in effective cancer therapy (Szakacs et al., 2006).”
BackgroundJi, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Teng, Q., Chen, Z., Kong, D., & Yang, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01236 · Cited by 69
“Multidrug resistance (MDR) remains a major challenge that contributes to the failure of cancer chemotherapy (Szakács et al., 2006; Kartal-Yandim et al., 2016).”
BackgroundInward- and outward-facing X-ray crystal structures of homodimeric P-glycoprotein CmABCB1
Kodan, A., Yamaguchi, T., Nakatsu, T., Matsuoka, K., Kimura, Y., Ueda, K., & Kato, H. (2019) · Nature Communications · doi:10.1038/s41467-018-08007-x · Cited by 69
Lin, X., Fang, Y., Tao, Z., Gao, X., Wang, T., Zhao, M., Wang, S., & Liu, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b07643 · Cited by 66
New inhibitors of ABCG2 identified by high-throughput screening
Henrich, C. J., Robey, R. W., Bokesch, H. R., Bates, S. E., Shukla, S., Ambudkar, S. V., Dean, M. C., & McMahon, J. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0352 · Cited by 70
“Because ABCG2 has overlapping substrate specificity with MRP1 and Pgp and because Pgp, MRP1, and ABCG2 are the major contributors to multidrug resistance in most cancer cells in culture (4), the selected compounds were tested for their ability to affect MRP1 and Pgp activities.”
BackgroundDong, Z., Hao, Y., Li, Q., Yang, Z., Zhu, Y., Liu, Z., & Feng, L. (2020) · Nano Research · doi:10.1007/s12274-020-2972-9 · Cited by 66
Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells
Khalili‐Tanha, G., & Moghbeli, M. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00282-9 · Cited by 69
“The resistance of the Table 1 All of the long non‑coding RNAs associated with Doxorubicin response in different cancers Cancer type DOX response LncRNA Target Samples Function References Breast cancer (BC) BC Resistance XIST miR-200c-3p / ANLN MDA‑MB‑231/ ADM and MDA‑MB‑231 cell lines XIST up regu‑ lated ANLN by spong…”
BackgroundInfluentialKuan, C.-Y., Walker, T., Luo, P. G., & Chen, C. (2011) · Journal of the American College of Nutrition · doi:10.1080/07315724.2011.10719969 · Cited by 72
Martin, A. P., Miller, A. V., Emad, L., Rahmani, M., Walker, T. D., Mitchell, C., Hagan, M. P., Park, M. A., Yacoub, A., Fisher, P. B., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047365 · Cited by 67
“Multidrug resistance pumps, overexpression of antiapoptotic molecules belonging to the BCL-2 family, and constitutive activity of NF B have also been linked to drug resistance in a wide variety of cancer cell types (Raffo et al., 1995; Cabannes et al., 1999; Sumitomo et al., 1999; Baldwin, 2001; Szakács et al., 2006).”
BackgroundNabekura, T., Hiroi, T., Kawasaki, T., & Uwai, Y. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.007 · Cited by 69
Li, X., Li, P., Zhang, Y., Zhou, Y., Chen, X., Huang, Y., & Liu, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0147-1 · Cited by 68
Zhu, X., Yuan, J., Leung, K. C., Lee, S., Sham, K. W. Y., Cheng, C. H. K., Au, D. W. T., Teng, G., Ahuja, A. T., & Wáng, Y. X. J. (2012) · Nanoscale · doi:10.1039/c2nr30960b · Cited by 68
Overcoming multiple drug resistance mechanisms in medulloblastoma
Othman, R. T., Kimishi, I., Bradshaw, T. D., Storer, L. C. D., Korshunov, A., Pfister, S. M., Grundy, R. G., Kerr, I. D., & Coyle, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-57 · Cited by 79
“Since four of the drugs currently being used to treat primary and recurrent MB are ABCB1 substrates (etoposide, vincristine, methotrexate and irinotecan) [27] we would anticipate that overcoming/inhibiting ABCB1 could enhance the efficacy of current chemotherapy regimens.”
BackgroundSelenorhodamine Photosensitizers for Photodynamic Therapy of P-Glycoprotein-Expressing Cancer Cells
Hill, J. E., Linder, M. K., Davies, K. S., Sawada, G. A., Morgan, J., Ohulchanskyy, T. Y., & Detty, M. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501259v · Cited by 65
Wang, F., Sun, Q., Feng, B., Xu, Z., Zhang, J., Xu, J., Lu, L., Yu, H., Wang, M., Li, Y., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600283 · Cited by 67
Tu, Y., & Zhu, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.024 · Cited by 67
Implications of ATP-binding cassette transporters for brain pharmacotherapies
Hermann, D. M., & Bassetti, C. L. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.01.007 · Cited by 75
PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Mairinger, S., Erker, T., Müller, M., & Langer, O. (2011) · Current Drug Metabolism · doi:10.2174/138920011798356980 · Cited by 71
“A major factor governing drug disposition in the body is the transport of drug molecules into and out of different body compartments by active transport proteins, such as those belonging to the adenosine triphosphate (ATP)-binding cassette superfamily [3-6].”
BackgroundTriangular Relationship between p53, Autophagy, and Chemotherapy Resistance
Xu, J., Patel, N. H., & Gewirtz, D. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238991 · Cited by 68
Liu, W., Chen, M.-T., Wang, M., Lee, Y., Chiou, G., Chien, C., Huang, P., Chen, Y., Huang, M., Chiou, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2737 · Cited by 65
“Three ATP-binding cassette (ABC) drug transporters have been associated with drug resistance in most cancers [55], and the ABCB1 (p-glycoprotein/MDR1), ABCC1 (MRP1) and ABCC2 (MRP2) subfamilies have been shown to be involved in the development of cisplatin resistance [56–59].”
BackgroundThe network of P-glycoprotein and microRNAs interactions
Lopes-Rodrigues, V., Seca, H., Sousa, D., Sousa, E., Lima, R. T., & Vasconcelos, M. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28500 · Cited by 76
“It is a 170 kDa membrane protein, member of the ATP-binding cassette (ABC) superfamily of transporters,(49) which acts to prevent the absorption of orally ingested or airborne toxins, xenobiotics or drugs.(50) P-gp is encoded by the human MDR-1 gene located at chromosome 7, being synthesized in the endoplasmic reticul…”
BackgroundHou, H., Sun, H., Lü, P., Ge, C., Zhang, L., Li, H., Zhao, F., Tian, H., Zhang, L., Chen, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0201 · Cited by 65
“expression is controlled in tumor cells and CSCs are currently unclear (10).”
BackgroundNanoparticle-based drug delivery systems: What can they really do in vivo?
Wang, Y.-F., Liu, L., Xue, X., & Liang, X. (2017) · F1000Research · doi:10.12688/f1000research.9690.1 · Cited by 75
Wang, Z., Sau, S., Alsaab, H. O., & Iyer, A. K. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.04.004 · Cited by 64
Impact of Galectins in Resistance to Anticancer Therapies
Navarro, P., Martínez‐Bosch, N., Blidner, A. G., & Rabinovich, G. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3870 · Cited by 67
“In particular, one key mechanism involved in Gal1-mediated chemoresistance is the overexpression of P-glycoprotein (encoded by the multidrug resistance gene 1,MDR1), which is one of the main ATP-binding cassette transporters involved in expelling cytotoxic drugs from the intracellular space (66).”
BackgroundRole of drug efflux carriers in the healthy and diseased brain
Hermann, D. M., Kılıç, E., Spudich, A., Krämer, S. D., Wunderli‐Allenspach, H., & Bassetti, C. L. (2006) · Annals of Neurology · doi:10.1002/ana.21012 · Cited by 68
“By assessing vesicles obtained from different types of cells (vesicles, in which efflux carriers are either overexpressed or knocked down), the affinity of drugs to efflux carriers may be evaluated.(51) Unfortunately, ATPase activity is a rather rough readout, which is still not sensitive at least for some drugs.”
BackgroundInfluentialKiran, M. S., Kumar, C. R. R., Shwetha, U. R., Onkarappa, H. S., Betageri, V. S., & Latha, M. S. (2021) · Chemical Data Collections · doi:10.1016/j.cdc.2021.100714 · Cited by 68
Fang, Z., Chen, S., Qin, J., Chen, B., Ni, G., Chen, Z., Zhou, J., Li, Z., Ning, Y., Wu, C., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.021 · Cited by 68
Huang, P., Wang, G., Su, Y., Zhou, Y., Huang, W., Zhang, R., & Yan, D. (2019) · Theranostics · doi:10.7150/thno.36163 · Cited by 65
“Among numerous complicated mechanisms of MDR, the overexpression of drug efflux pumps, such as P-glycoprotein (P-gp), belonging to the family of ATP-binding cassette (ABC) transporter, is one of the most major cause [1].”
BackgroundJain, N., Kalam, H., Singh, L., Sharma, V., Kedia, S., Das, P., Ahuja, V., & Kumar, D. (2020) · Nature Communications · doi:10.1038/s41467-020-16877-3 · Cited by 65
Review of Curcumin Physicochemical Targeting Delivery System
Li, L., Zhang, X., Pi, C., Yang, H., Zheng, X., Zhao, L., & Wei, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s276201 · Cited by 63
Rybenkov, V. V., Zgurskaya, H. I., Ganguly, C., Leus, I. V., Zhang, Z., & Moniruzzaman, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01137 · Cited by 68
Triazole-fused pyrimidines in target-based anticancer drug discovery
Dai, X., Xue, L.-P., Ji, S., Zhou, Y., Gao, Y., Zheng, Y., Liu, H., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115101 · Cited by 66
Ce6 nanoassemblies: Molecular mechanism and strategies for combinational anticancer therapy
Liu, Y., Xu, S., Lyu, Q., Huang, Y., & Wang, W. (2023) · Aggregate · doi:10.1002/agt2.443 · Cited by 67
Ivnitski‐Steele, I. D., Larson, R. A., Lovato, D. M., Khawaja, H. M., Winter, S. S., Oprea, T. I., Sklar, L. A., & Edwards, B. S. (2008) · Assay and Drug Development Technologies · doi:10.1089/adt.2007.107 · Cited by 66
“24,25 A variety of modulators, such as cyclosporin A, quinine, trifluoperazine, droloxifene, to-moxifen, toremifene, desniuldipine, verapamil, dexvera-pamil, PSC 833, and GF 120198, are now undergoing clinical trials.”
Yuan, J., Wong, I. L. K., Jiang, T., Wang, S. W., Liu, T., Wen, B. J., Chow, L. M. C., & Sheng, B. W. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.05.026 · Cited by 67
Rahgozar, S., Moafi, A., Abedi, M., Ghaem, M. E. E., Moshtaghian, J., Ghaedi, K., Esmaeili, A., & Montazeri, F. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26603 · Cited by 63
Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans
Macdonald, N., & Gledhill, A. J. (2007) · Archives of Toxicology · doi:10.1007/s00204-007-0193-6 · Cited by 63
“brane organic anion transporter/CMOAT) and breast cancer drug resistance protein (ABCG2/BCRP/mitoxantroneresistance protein/MXR) (Szakacs et al. 2006).”
BackgroundIns and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays
Hegedüs, C., Szakács, G., Homolya, L., Orbán, T. I., Telbisz, Á., Jani, M., & Sarkadi, B. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.007 · Cited by 71
Self-citationAbraham, I., Jain, S. K., Wu, C., Khanfar, M. A., Kuang, Y., Dai, C.-L., Shi, Z., Chen, X., Fu, L., Ambudkar, S. V., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.001 · Cited by 64
“Examples of P-gp substrates include Vinca alkaloids (vincristine, vinblastine), anthracyclines (doxorubicin, daunorubicin, epirubicin), epipodophyllotoxins (etoposide, teniposide) and taxanes [4].”
BackgroundNanotechnologies for the treatment of colon cancer: From old drugs to new hope
Kotelevets, L., Chastre, E., Desmaële, D., & Couvreur, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.005 · Cited by 66
Thermo-Sensitive Vesicles in Controlled Drug Delivery for Chemotherapy
Mazzotta, E., Tavano, L., & Muzzalupo, R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030150 · Cited by 66
“Generally, chemotherapeutics are administered intravenously and, due to their systemic distribution, the therapeutic effect at the tumour site is achieved only after high dose administration, often causing resistance and severe adverse effects [2,3].”
BackgroundWang, T., Luo, Y., Lv, H., Wang, J., Zhang, Y., & Pei, R. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b16637 · Cited by 67
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.